11.06.25 -- Scaling Allogeneic NK Cell Therapies

Discover how pharmaceutical isolators optimize operations, achieve higher sterility assurance, and meet stringent regulatory requirements. Learn about design principles, validation, and VHP cycles.

Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.

Explore a practical guide to selecting filters for bioprocessing applications that are matched to product type, process stage, and performance needs such as virus filtration, clarification, and TFF.

Assimilate how new processing methods tackle challenges in large-scale stem cell production and how automated, low-shear processing maintains cell health and pluripotency across production scales.

The FDA’s Advanced Manufacturing Technologies (AMT) Designation Program is identifying innovative technologies that enable scalable CGT production to help transformative therapies reach patients.

What must we do as an industry to continue the momentum of cell and gene therapies and ensure these revolutionary treatments become a reality for patients who need them?

This study demonstrates the ability of combined platforms with complimentary technologies to modify primary T cells in a functionally-closed, automated fashion.

Delve into the intricacies of Impingement Jets Mixing (IJM) technology and its pivotal role in the scalable and reproducible production of Lipid Nanoparticles (LNPs) for drug delivery.

Achieving high-quality viral vectors demands rigorous control over contaminants. Learn about enzymatic approaches to significantly reduce nucleic acid impurities in your manufacturing processes.

Automated bioprocessing can significantly improve CAR T cell manufacturing by reducing errors and enhancing scalability. Explore how this approach supports consistent, high-quality cell therapy production.